Fri, September 9, 2022 (HealthDay News) – People who want to stay wrinkles At bay will soon have a new option now that the US Food and Drug Administration has approved its number one competitor Botox in decades.
Daxxify, which is made by Revance Therapeutics Inc., is injected. In Nashville, Tennessee, in the face along the lines of concern. It lasts longer than Botox, with about 80% of users seeing no or no light facial lines four months after the injection. Half of the users continued the treatment for six months, the company said in a statement.
“Users don’t have to go once every three months,” said Dr Balaji Prasad, who covers specialty pharmaceuticals as an analyst for Barclays Investment Bank. The New York Times. “In a world where time is of the essence, having a product with a long duration factor is very beneficial.”
The new drug is now entering the $3 billion face injection drug business. It is also a neuromuscular blocking agent and botulinum toxin, like Abbvie’s Botox.
Mark Foley, CEO of Revance, told times. “If you are thinking of Migrainescervical dystonia [a neurological condition that affects the muscles in the neck and shoulders]And the overactive bladderThere is a huge medical opportunity, too.”
Foley said the company has begun testing the drug for these other medical issues. While the company was trying to create a product that didn’t require a needle, it instead discovered a way to use peptide technology to keep the product stable. Usually, animal protein or human serum is used.
Botox is also used for more than just wrinkles. It’s been an FDA-approved treatment for chronic migraines since 2010.
Daxxify users in the Revance studies included some who experienced side effects. About 2% of people developed ptosis, while about 6% experienced headaches, the company said.
The U.S. Food and Drug Administration has warned that toxicology-based therapy can carry other side effects, such as general muscle weakness or breathing difficulties. Participants in the Daxxify study showed none of these symptoms.
Revance had initially hoped to have its product approved in November 2020, but plans have been delayed due to pandemic travel restrictions. times mentioned. An examination finally conducted in June 2021 found problems with the quality control process and the company’s working cell bank, which contains the active ingredient of the drug. These concerns have been resolved times mentioned.
The National Library of Medicine has more on botulinum toxin.